Zacks Research Issues Pessimistic Forecast for BAX Earnings

Baxter International Inc. (NYSE:BAX) – Zacks Research reduced their Q2 2026 earnings estimates for shares of Baxter International in a note issued to investors on Tuesday, July 14th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.36 per share for the quarter, down from their prior forecast of $0.37. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $1.91 per share. Zacks Research also issued estimates for Baxter International’s Q3 2026 earnings at $0.50 EPS, FY2026 earnings at $1.83 EPS, Q3 2027 earnings at $0.54 EPS, FY2027 earnings at $1.90 EPS and FY2028 earnings at $2.13 EPS.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The business had revenue of $2.70 billion during the quarter, compared to analyst estimates of $2.62 billion. During the same period in the previous year, the company posted $0.62 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year.

Several other equities research analysts also recently commented on BAX. Barclays boosted their price objective on Baxter International from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, May 1st. TD Cowen reduced their price target on shares of Baxter International from $22.00 to $20.00 in a research report on Friday, May 1st. Citigroup lowered shares of Baxter International from a “neutral” rating to a “sell” rating and decreased their price target for the company from $19.00 to $17.00 in a research note on Thursday, May 28th. Evercore lowered their price objective on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Finally, Stifel Nicolaus dropped their price objective on shares of Baxter International from $20.00 to $19.00 in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $19.91.

Baxter International Stock Up 5.5%

Shares of NYSE:BAX opened at $23.36 on Wednesday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.23 and a current ratio of 1.85. Baxter International has a 52-week low of $15.73 and a 52-week high of $29.35. The business’s 50 day simple moving average is $20.16 and its two-hundred day simple moving average is $19.33. The firm has a market cap of $12.06 billion, a P/E ratio of -10.97, a PEG ratio of 3.58 and a beta of 0.62.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th were paid a $0.01 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is -1.88%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BAX. Geode Capital Management LLC grew its holdings in Baxter International by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock worth $257,174,000 after buying an additional 972,891 shares in the last quarter. Greenhaven Associates Inc. lifted its stake in Baxter International by 70.0% during the 4th quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier’s stock valued at $204,347,000 after acquiring an additional 4,404,874 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Baxter International by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after acquiring an additional 97,687 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Baxter International by 35.6% during the 4th quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock worth $65,216,000 after acquiring an additional 894,761 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC boosted its holdings in Baxter International by 12.0% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 3,328,202 shares of the medical instruments supplier’s stock worth $63,602,000 after acquiring an additional 356,612 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Goldman Sachs raised its price target on Baxter International to $21 from $19, signaling somewhat improved valuation expectations even though the firm kept a neutral rating. Baxter International (NYSE:BAX) Given New $21.00 Price Target at The Goldman Sachs Group
• Neutral Sentiment: News also highlighted that Baxter’s chart has formed a golden cross, a technical signal some traders view as constructive for near-term momentum. AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
• Negative Sentiment: Zacks Research cut its earnings estimates for Baxter across multiple periods, including Q2 2026, FY2026, FY2027 and FY2028, while also downgrading the stock to Strong Sell, which suggests concerns about profit growth. Zacks.com downgrade
• Neutral Sentiment: Baxter also updated its segment reporting structure and metrics, but the filing did not appear to include a major operating surprise. Baxter International Updates Segment Reporting Structure and Metrics

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.